BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Mangia A, Rina MF, Canosa A, Piazzolla V, Squillante MM, Agostinacchio E, Cocomazzi G, Visaggi E, Augello N, Iannuzziello C, Falcone M, De Giorgi A, Campanozzi F. Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. United European Gastroenterol J 2021;9:1109-18. [PMID: 34697911 DOI: 10.1002/ueg2.12156] [Reference Citation Analysis]
2 Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int 2019;2019:2301291. [PMID: 31815126 DOI: 10.1155/2019/2301291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]